Exciting! FDA approves a new oncology drug that targets a key genetic driver of cancer.

  • News

The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there are no effective treatments.

Read the full article here.

Back To News